Flush with more than $40 million in capital, Triad integrated research organization Javara says it’s getting ready to “revolutionize” the quality of clinical trials and, ultimately, patient outcomes.
Flush with more than $40 million in capital, Triad clinical research firm Javara says it’s getting ready to “revolutionize” the quality of clinical trials and, ultimately, patient outcomes.